Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study
- Conditions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2089
- Registration Number
- NCT06021366
- Locations
- 🇵🇹
Novartis, Porto Salvo, Portugal
A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06019637
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
- Conditions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 946
- Registration Number
- NCT06018571
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT06006559
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1250
- Registration Number
- NCT06004453
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06004661
- Locations
- 🇪🇸
Novartis Investigative Site, El Palmar, Murcia, Spain
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT05996835
- Locations
- 🇺🇸
UC San Francisco Medical Center, San Francisco, California, United States
🇺🇸Montefiore Medical Center Montefiore Medical Center, Bronx, New York, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT05985915
- Locations
- 🇺🇸
North GA Rheumatology Group PC, Duluth, Georgia, United States
🇺🇸University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸STAT Research Inc, Dayton, Ohio, United States
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05983198
- Locations
- 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancy, France
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1093
- Registration Number
- NCT05982886
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States